thalidomide has been researched along with Neuroblastoma in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma by suppressing NF-κB." | 7.88 | Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation. ( Ashizuka, S; Baba, Y; Harada, A; Hiramatsu, T; Kaji, S; Kanamori, D; Miyaguni, K; Ohki, T; Sugihara, T; Uchida, G; Yoshizawa, J, 2018) |
| "Purified NK cells were cultured with IL-2, neuroblastoma/monocyte-conditioned culture medium (CM), IL-6, TGFβ1, and lenalidomide in various combinations and then characterized using cytotoxicity (direct and antibody-dependent cell-mediated cytotoxicity), cytokine, flow cytometry, and Western blotting assays." | 7.79 | Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. ( Asgharzadeh, S; Liu, WY; Seeger, RC; Sheard, MA; Sposto, R; Sun, J; Tran, HC; Wan, Z; Wu, HW; Xu, Y, 2013) |
| "Thalidomide treatment did not significantly alter tumor growth as compared with controls." | 5.32 | Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. ( Beck, L; Frischer, JS; Huang, J; Kadenhe-Chiweshe, A; Kaicker, S; Kandel, JJ; McCrudden, KW; New, T; Serur, A; Yamashiro, DJ; Yokoi, A, 2003) |
| "Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma by suppressing NF-κB." | 3.88 | Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation. ( Ashizuka, S; Baba, Y; Harada, A; Hiramatsu, T; Kaji, S; Kanamori, D; Miyaguni, K; Ohki, T; Sugihara, T; Uchida, G; Yoshizawa, J, 2018) |
| "Purified NK cells were cultured with IL-2, neuroblastoma/monocyte-conditioned culture medium (CM), IL-6, TGFβ1, and lenalidomide in various combinations and then characterized using cytotoxicity (direct and antibody-dependent cell-mediated cytotoxicity), cytokine, flow cytometry, and Western blotting assays." | 3.79 | Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. ( Asgharzadeh, S; Liu, WY; Seeger, RC; Sheard, MA; Sposto, R; Sun, J; Tran, HC; Wan, Z; Wu, HW; Xu, Y, 2013) |
| " Here we report that various NSAIDs, such as the cyclooxygenase inhibitors, nimesulide, ibuprofen and indomethacin, as well as thalidomide (Thal) and its non-teratogenic analogue, supidimide, significantly stimulated the secretion of the non-amyloidogenic alpha-secretase form of the soluble amyloid precursor protein (sAPP alpha) into the conditioned media of SH-SY5Y neuroblastoma and PC12 cells." | 3.71 | Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. ( Amit, T; Avramovich, Y; Youdim, MB, 2002) |
| "Thalidomide treatment did not significantly alter tumor growth as compared with controls." | 1.32 | Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. ( Beck, L; Frischer, JS; Huang, J; Kadenhe-Chiweshe, A; Kaicker, S; Kandel, JJ; McCrudden, KW; New, T; Serur, A; Yamashiro, DJ; Yokoi, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Rishfi, M | 1 |
| Krols, S | 1 |
| Martens, F | 1 |
| Bekaert, SL | 1 |
| Sanders, E | 1 |
| Eggermont, A | 1 |
| De Vloed, F | 1 |
| Goulding, JR | 1 |
| Risseeuw, M | 1 |
| Molenaar, J | 1 |
| De Wilde, B | 1 |
| Van Calenbergh, S | 1 |
| Durinck, K | 1 |
| Hiramatsu, T | 1 |
| Yoshizawa, J | 1 |
| Miyaguni, K | 1 |
| Sugihara, T | 1 |
| Harada, A | 1 |
| Kaji, S | 1 |
| Uchida, G | 1 |
| Kanamori, D | 1 |
| Baba, Y | 1 |
| Ashizuka, S | 1 |
| Ohki, T | 1 |
| Xu, Y | 1 |
| Sun, J | 1 |
| Sheard, MA | 1 |
| Tran, HC | 1 |
| Wan, Z | 1 |
| Liu, WY | 1 |
| Asgharzadeh, S | 1 |
| Sposto, R | 1 |
| Wu, HW | 1 |
| Seeger, RC | 1 |
| Raszewski, G | 1 |
| Lemieszek, MK | 1 |
| Łukawski, K | 1 |
| Juszczak, M | 1 |
| Rzeski, W | 1 |
| Kaicker, S | 1 |
| McCrudden, KW | 1 |
| Beck, L | 1 |
| New, T | 1 |
| Huang, J | 1 |
| Frischer, JS | 1 |
| Serur, A | 1 |
| Kadenhe-Chiweshe, A | 1 |
| Yokoi, A | 1 |
| Kandel, JJ | 1 |
| Yamashiro, DJ | 1 |
| Ribatti, D | 1 |
| Ponzoni, M | 1 |
| Gesundheit, B | 1 |
| Moser, A | 1 |
| Or, R | 1 |
| Klement, G | 1 |
| Avramovich, Y | 1 |
| Amit, T | 1 |
| Youdim, MB | 1 |
1 review available for thalidomide and Neuroblastoma
| Article | Year |
|---|---|
Antiangiogenic strategies in neuroblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cyclohexanes; Disea | 2005 |
7 other studies available for thalidomide and Neuroblastoma
| Article | Year |
|---|---|
Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.
Topics: Aurora Kinase A; Cell Line, Tumor; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; Thalidomide | 2023 |
Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.
Topics: Animals; Apoptosis; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplast | 2018 |
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Culture Media, Conditioned; Female; Humans; Interleuk | 2013 |
Chlorpyrifos and cypermethrin induce apoptosis in human neuroblastoma cell line SH-SY5Y.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Cell Line, Tumor; Chlorpyrifos; Dose-Response Relationsh | 2015 |
Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Endothelium, Vascular; Humans; Immunohistochemis | 2003 |
Successful antiangiogenic therapy for neuroblastoma with thalidomide.
Topics: Angiogenesis Inhibitors; Child, Preschool; Humans; Male; Neuroblastoma; Thalidomide | 2007 |
Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein.
Topics: Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inh | 2002 |